-
公开(公告)号：US20230232797A1
公开(公告)日：2023-07-27
申请号：US18175010
申请日：2023-02-27
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Qing Fang , Chia-Jen Siao , Dan Chalothorn , KehDih Lai , Leah Sabin , Rachel Sattler , Brian Zambrowicz , Lori Morton
IPC: A01K67/027 , A61K49/00 , C07K14/76 , C12N15/85
CPC classification number: A01K67/0278 , A61K49/0008 , C07K14/76 , C12N15/8509 , A01K2207/15 , A01K2227/105 , A01K2267/03 , C12N2015/8527
Abstract: Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized albumin (ALB) locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized albumin locus express a human albumin protein or a chimeric albumin protein, fragments of which are from human albumin. Methods are provided for using such non-human animals comprising a humanized albumin locus to assess in vivo efficacy of human-albumin-targeting reagents such as nuclease agents designed to target human albumin.
-
公开(公告)号：US11737435B2
公开(公告)日：2023-08-29
申请号：US16838519
申请日：2020-04-02
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Yajun Tang , Dan Chalothorn , Lyndon Mitnaul , Lori Morton , Daria Zamolodchikov , Nicole Alessandri-Haber , Lynn Macdonald
IPC: A01K67/027 , C07K14/745 , C12Q1/6876 , C12N9/22 , C12N15/86
CPC classification number: A01K67/0278 , C07K14/745 , C12N9/22 , C12N15/86 , C12Q1/6876 , A01K2207/15 , A01K2217/072 , A01K2217/203 , C12N2310/20
Abstract: Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized coagulation factor XII (F12) locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized F12 locus express a human coagulation factor XII protein or a chimeric coagulation factor XII protein, fragments of which are from human coagulation factor XII. Methods are provided for using such non-human animals comprising a humanized F12 locus to assess in vivo efficacy of human-coagulation-factor-XII-targeting reagents such as nuclease agents designed to target human F12. A short isoform of F12 that is produced locally in the brain, and methods of using the short isoform, are also provide.
-
公开(公告)号：US12201096B2
公开(公告)日：2025-01-21
申请号：US18347009
申请日：2023-07-05
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Yajun Tang , Dan Chalothorn , Lyndon Mitnaul , Lori Morton , Daria Zamolodchikov , Nicole Alessandri-Haber , Lynn Macdonald
IPC: A01K67/0278 , C07K14/745 , C12N9/22 , C12N15/86 , C12Q1/6876
Abstract: Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized coagulation factor XII (F12) locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized F12 locus express a human coagulation factor XII protein or a chimeric coagulation factor XII protein, fragments of which are from human coagulation factor XII. Methods are provided for using such non-human animals comprising a humanized F12 locus to assess in vivo efficacy of human-coagulation-factor-XII-targeting reagents such as nuclease agents designed to target human F12. A short isoform of F12 that is produced locally in the brain, and methods of using the short isoform, are also provide.
-
公开(公告)号：US20230131338A1
公开(公告)日：2023-04-27
申请号：US18048644
申请日：2022-10-21
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Dan Chalothorn , Lori C. Morton , KehDih Lai
Abstract: The present disclosure provides antibodies that bind to the A2 domain of Factor XI (FXI) and methods of using the same. According to certain embodiments, the antibodies are antagonist antibodies that inhibit blood clot formation via the intrinsic pathway without affecting hemostasis, as shown by their effect on prolonging aPTT without affecting PT. As such, these antagonist antibodies may be used to treat blood clotting diseases or disorders or treatment regimens that have clot formation as a risk factor, such as, but not limited to atrial fibrillation. In certain embodiments, the disclosure includes antibodies that bind FXI and mediate clot formation or thrombogenesis. The antibodies of the disclosure may be fully human, non-naturally occurring antibodies.
-
5.发明申请
公开(公告)号：US20180057580A1
公开(公告)日：2018-03-01
申请号：US15684073
申请日：2017-08-23
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Dan Chalothorn , Lori C. Morton
IPC: C07K16/24 , A61K39/395 , A61K45/06
CPC classification number: C07K16/24 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/22 , C07K2317/21 , C07K2317/24 , C07K2317/76
Abstract: The present invention provides anti-Gremlin-1 (GREM1) antibodies, and antigen-binding fragments thereof, as well as methods of use of such antibodies, or antigen-binding fragments thereof, for treating a subject having pulmonary arterial hypertension (PAH).
-
公开(公告)号：US11622547B2
公开(公告)日：2023-04-11
申请号：US16894302
申请日：2020-06-05
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Qing Fang , Chia-Jen Siao , Dan Chalothorn , KehDih Lai , Leah Sabin , Rachel Sattler , Brian Zambrowicz , Lori Morton
IPC: A01K67/027 , A61K49/00 , C07K14/76 , C12N15/85
Abstract: Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized albumin (ALB) locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized albumin locus express a human albumin protein or a chimeric albumin protein, fragments of which are from human albumin. Methods are provided for using such non-human animals comprising a humanized albumin locus to assess in vivo efficacy of human-albumin-targeting reagents such as nuclease agents designed to target human albumin.
-
公开(公告)号：US20200315149A1
公开(公告)日：2020-10-08
申请号：US16838519
申请日：2020-04-02
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Yajun Tang , Dan Chalothorn , Lyndon Mitnaul , Lori Morton , Daria Zamolodchikov , Nicole Alessandri-Haber , Lynn Macdonald
IPC: A01K67/027 , C12N9/22 , C12Q1/6876 , C12N15/86 , C07K14/745
Abstract: Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized coagulation factor XII (F12) locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized F12 locus express a human coagulation factor XII protein or a chimeric coagulation factor XII protein, fragments of which are from human coagulation factor XII. Methods are provided for using such non-human animals comprising a humanized F12 locus to assess in vivo efficacy of human-coagulation-factor-XII-targeting reagents such as nuclease agents designed to target human F12. A short isoform of F12 that is produced locally in the brain, and methods of using the short isoform, are also provide.
-
8.发明申请
公开(公告)号：US20180008672A1
公开(公告)日：2018-01-11
申请号：US15643539
申请日：2017-07-07
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Dan Chalothorn , Lori C. Morton
IPC: A61K38/18 , C07K16/28 , A61K39/00 , C07K14/495 , C12N15/09
CPC classification number: A61K38/1841 , A61K39/00 , A61K39/3955 , C07K14/495 , C07K16/22 , C07K16/2863 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2319/30 , C07K2319/32 , C12N15/09
Abstract: The present invention provides anti-Activin A antibodies, and antigen-binding fragments thereof, as well as methods of use of such antibodies, or antigen-binding fragments thereof, for treating a subject having pulmonary arterial hypertension (PAH).
-
公开(公告)号：US12068729B2
公开(公告)日：2024-08-20
申请号：US17253279
申请日：2019-06-19
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Dan Chalothorn , Lori C. Morton , Lyndon Mitnaul , KehDih Lai
CPC classification number: H03F3/45475 , H03F2203/45444
Abstract: The present invention provides monoclonal antibodies that bind to the Factor XII (FXII) protein, and methods of use thereof. In various embodiments of the invention, the antibodies are fully human antibodies that bind to FXII and to the activated form of FXII (FXIIa). In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing FXII activity, thus providing a means of treating or preventing a disease, disorder or condition associated with thrombosis in humans.
-
公开(公告)号：US20240190996A1
公开(公告)日：2024-06-13
申请号：US18387658
申请日：2023-11-07
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Dan Chalothorn , Lori C. Morton , KehDih Lai
CPC classification number: C07K16/36 , A61P7/02 , C12N15/63 , A61K2039/505 , C07K2317/565 , C07K2317/92 , C07K2317/94
Abstract: The present disclosure provides antibodies that bind to the catalytic domain of Factor XI (FXI) and methods of using the same. According to certain embodiments, the antibodies are antagonist antibodies that inhibit blood clot formation via the intrinsic pathway without affecting hemostasis, as shown by their effect on prolonging aPTT without affecting PT. As such, these antagonist antibodies may be used to treat blood clotting diseases or disorders or treatment regimens that have clot formation as a risk factor, such as, but not limited to atrial fibrillation. In certain embodiments, the disclosure includes antibodies that bind FXI and mediate clot formation or thrombogenesis. The antibodies of the disclosure may be fully human, non-naturally occurring antibodies.
